Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores

Affiliations

• ¹ Department of Medicine, Endocrinology and Metabolism, University of Verona, Verona, Veneto, Italy giovanni.targher@univr.it zhengmh@wmu.edu.cn.
• ² Department of Medicine, Endocrinology and Metabolism, University of Verona, Verona, Veneto, Italy.
• ³ Southampton National Institute for Health Research Biomedical Research Centre, Southampton General Hospital, Southampton, Hampshire, UK.
• ⁴ Department of Critical Care Medicine, Wenzhou Medical College First Affiliated Hospital, Wenzhou, Zhejiang, China.
• ⁵ Department of Hepatology, Ningbo No 2 Hospital, Ningbo, Zhejiang, China.
• ⁶ Department of Radiology, Wenzhou Medical University First Affiliated Hospital, Wenzhou, Zhejiang, China.
• ⁷ NAFLD Research Center, Department of Hepatology, Wenzhou Medical College First Affiliated Hospital, Wenzhou, Zhejiang, China.
• ⁸ Department of Infection and Liver Diseases, Liver Research Center, Wenzhou Medical College First Affiliated Hospital, Wenzhou, Zhejiang, China.
• ⁹ Storr Liver Centre, Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
• ¹⁰ NAFLD Research Center, Department of Hepatology, Wenzhou Medical College First Affiliated Hospital, Wenzhou, Zhejiang, China giovanni.targher@univr.it zhengmh@wmu.edu.cn.
• ¹¹ Institute of Hepatology, Wenzhou Medical University, Wenzhou, Zhejiang, China.